Meeting Banner
Abstract #2759

Metabolic dynamics of hyperpolarized [1-13C] pyruvate in human prostate cancer

Kristin L Granlund1,2, Hebert A Vargas1, Serge K Lyashchenko3, Phillip J DeNoble3, Vincent A Laudone4, James Eastham4, Ramon A Sosa1, Matthew A Kennedy1, Duane Nicholson1, YanWei W Guo1, Albert P Chen5, James Tropp6, Hedvig Hricak1,2, and Kayvan R Keshari1,2

1Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 2Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 3Radiochemistry & Imaging Probes (RMIP) Core, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 4Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 5GE Healthcare, Toronto, ON, Canada, 6GE Healthcare, Fremont, CA, United States

Hyperpolarized (HP) pyruvate has the potential to improve tumor grading and evaluate response to treatment by probing the metabolism of lesions. Three patients with biopsy-proven prostate cancers have been scanned with a 2D dynamic hyperpolarized pyruvate protocol. Repeatability has been evaluated in 2 patients to date. The data from these first 5 injections confirm that HP prostate imaging is feasible and reproducible, and the 2D dynamics will inform 3D static acquisition timing.

This abstract and the presentation materials are available to members only; a login is required.

Join Here